QuidelOrtho 10-Q 24 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 20, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	QUIDEL CORP /DE/
Entity Central Index Key	353569
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Name	QDEL
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus (Q1,Q2,Q3,FY)	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		34,493,213

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$229,429	$200,895
Accounts receivable, net	18,676	34,466
Inventories	22,894	24,763
Deferred tax asset—current	7,460	8,316
Restricted cash	3,465	3,127
Prepaid expenses and other current assets	3,367	2,914
Total current assets	285,291	274,481
Property, plant and equipment, net	49,315	49,226
Goodwill	80,729	80,748
Intangible assets, net	38,858	41,890
Other non-current assets	1,000	1,066
Total assets	455,193	447,411
Current liabilities:
Accounts payable	8,485	12,421
Accrued payroll and related expenses	7,365	8,349
Current portion of lease obligation	576	509
Current portion of contingent consideration (see Note 9)	598	733
Deferred grant revenue	5,118	6,330
Other current liabilities	13,980	8,043
Total current liabilities	36,122	36,385
Long-term debt	139,276	137,958
Lease obligation, net of current portion	4,429	4,617
Contingent consideration—non-current (see Note 9)	5,006	5,023
Deferred tax liability—non-current	15,315	14,890
Income taxes payable	806	806
Deferred rent	2,273	2,228
Other non-current liabilities	515	493
Commitments and contingencies (see Note 9)
Stockholders’ equity:
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at March 31, 2015 and December 31, 2014	0	0
Common stock, $.001 par value per share; 50,000 shares authorized; 34,489 and 34,433 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	34	34
Additional paid-in capital	231,806	229,374
Accumulated other comprehensive loss	-12	-29
Retained earnings	19,623	15,632
Total stockholders’ equity	251,451	245,011
Total liabilities and stockholders’ equity	$455,193	$447,411

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Per Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	50,000	50,000
Common stock, shares issued	34,489	34,433
Common stock, shares outstanding	34,489	34,433

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Total revenues	$61,302	$46,673
Costs and expenses
Cost of sales (excludes amortization of intangible assets of $1,571 in both 2015 and 2014)	21,112	20,247
Research and development	8,051	9,081
Sales and marketing	11,389	9,927
General and administrative	9,860	7,226
Amortization of intangible assets from acquired businesses and technology	2,201	2,208
Total costs and expenses	52,613	48,689
Operating income (loss)	8,689	-2,016
Interest expense, net	-2,895	-360
Income (loss) before provision for income taxes	5,794	-2,376
Provision (benefit) for income taxes	1,803	-864
Net income (loss)	$3,991	($1,512)
Basic earnings (loss) per share	$0.12	($0.04)
Diluted earnings (loss) per share	$0.11	($0.04)
Shares used in basic per share calculation	34,641	34,199
Shares used in diluted per share calculation	35,745	34,199

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Amortization of intangible assets	$1,571	$1,571

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$3,991	($1,512)
Other comprehensive income (loss), net of tax
Changes in cumulative translation adjustment	17	-11
Comprehensive income (loss)	$4,008	($1,523)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES:
Net income (loss)	$3,991	($1,512)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation, amortization and other	6,202	7,332
Stock-based compensation expense	2,068	2,237
Amortization of debt discount and deferred issuance costs	1,399	84
Change in deferred tax assets and liabilities	1,285	0
Change in fair value of acquisition contingencies	0	42
Changes in assets and liabilities:
Accounts receivable	15,782	13,252
Inventories	786	2,655
Income taxes receivable	372	-944
Prepaid expenses and other current and non-current assets	-457	-1,002
Restricted cash	-338	423
Accounts payable	-3,196	-596
Accrued payroll and related expenses	-870	-559
Income taxes payable	-2	-9
Deferred grant revenue	-1,212	-653
Other current and non-current liabilities	5,956	1,407
Net cash provided by operating activities	31,766	22,157
INVESTING ACTIVITIES:
Acquisitions of property and equipment	-2,867	-3,967
Acquisition of intangibles	0	-92
Net cash used for investing activities	-2,867	-4,059
FINANCING ACTIVITIES:
Payments on lease obligation	-121	-105
Repurchases of common stock	-337	-1,951
Proceeds from issuance of common stock	596	1,839
Payments of debt issuance costs	-365	0
Payments on acquisition contingencies	-129	-1,109
Net cash used for financing activities	-356	-1,326
Effect of exchange rates on cash	-9	0
Net increase in cash and cash equivalents	28,534	16,772
Cash and cash equivalents, beginning of period	200,895	8,388
Cash and cash equivalents, end of period	229,429	25,160
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	250	346
Cash paid for income taxes	121	51
NON-CASH INVESTING ACTIVITIES:
Purchase of capital equipment by incurring current liabilities	164	760
NON-CASH FINANCING ACTIVITIES:
Reduction of other current liabilities upon issuance of restricted share units	$408	$663

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying unaudited consolidated financial statements of Quidel Corporation and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) have been included.
	The information at March 31, 2015, and for the three months ended March 31, 2015 and 2014, is unaudited. For further information, refer to the Company’s consolidated financial statements and footnotes thereto for the year ended December 31, 2014 included in the Company’s 2014 Annual Report on Form 10-K. Operating results for any quarter are historically seasonal in nature and are not necessarily indicative of the results expected for the full year.
	The Company recorded an immaterial reclassification of $0.2 million for the three months ended March 31, 2014 from general and administrative expense as previously reported in the Consolidated Statements of Operations to conform to current year interest expense presentation. The amortization of debt issuance costs and loan commitment fees had previously been recorded in general and administrative expense in the Consolidated Statements of Operations and the Company reclassified the amounts to more appropriately identify them as interest expense. The reclassification did not impact net income as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Cash Flows, or Statements of Comprehensive Income (Loss). Management evaluated the materiality of these prior year reclassifications both qualitatively and quantitatively and determined that these errors were not material to the previously reported financial statements.
	For 2015 and 2014, the Company’s fiscal year will end or has ended on January 3, 2016 and December 28, 2014, respectively. For 2015 and 2014, the Company’s first quarter ended on March 29, 2015 and March 30, 2014, respectively. For ease of reference, the calendar quarter end dates are used herein. The three month periods ended March 31, 2015 and 2014 each included 13 weeks, respectively.
	Change in Accounting Principle
	The Company historically presented deferred debt issuance costs, or fees related to directly issuing debt, as assets on the consolidated balance sheets. During the first quarter of 2015, the Company adopted guidance codified in ASU 2015-03 Interest - Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs. The guidance simplifies the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs is not affected. Therefore, these costs will continue to be amortized as interest expense using the effective interest method pursuant to ASC 835-30-35-2 through 35-3. Upon adoption, the Company applied the new guidance retrospectively to all prior periods presented in the financial statements. The Company elected to early adopt the requirements of ASU 2015-03 effective beginning the first quarter ending March 31, 2015 and applied this guidance retrospectively to all prior periods presented in the Company's financial statements.
	The reclassification does not impact net income as previously reported or any prior amounts reported on the Statements of Comprehensive Income (Loss), or the Consolidated Statement of Cash Flows. The following table presents the effect of the retrospective application of this change in accounting principle on the Company’s Consolidated Balance Sheets as of December 31, 2014:
	Consolidated Balance Sheets (in thousands)	As Reported December 31, 2014		Effect of Change in Accounting Principle			After change in Accounting Principle
	ASSETS
	Current assets:
	Prepaid expenses and other current assets	$	3,554	$	(640	)	$	2,914
	Total current assets	275,121		(640		)	274,481
	Other non-current assets	4,565		(3,499		)	1,066
	Total assets	451,550		(4,139		)	447,411
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Long-term debt	142,097		(4,139		)	137,958
	Total liabilities and stockholders’ equity	451,550		(4,139		)	447,411
	Comprehensive Income (Loss)
	Comprehensive income (loss) includes foreign currency translation adjustments excluded from the Company’s Consolidated Statements of Operations.
	Use of Estimates
	The preparation of financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, management evaluates its estimates, including those related to revenue recognition, customer programs and incentives, bad debts, inventories, intangible assets, software development costs, stock-based compensation, restructuring, contingencies and litigation, contingent consideration, the fair value of the debt component of convertible debt instruments, and income taxes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
	Revenue Recognition
	The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts that are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenue from product sales are recorded upon passage of title and risk of loss to the customer. Passage of title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return.
	A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheet as property and equipment. The instrument is depreciated on a straight-line basis over the shorter of the lease term or the life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Operations. The reagent rental agreements represent one unit of accounting as the instrument and consumables (reagents) are interdependent in producing a diagnostic result and neither has a stand-alone value with respect to these agreements. No revenue is recognized at the time of instrument placement. All revenue is recognized when the title and risk of loss for the diagnostic kits have passed to the customer.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. The Company also earns income from the licensing of technology.
	The Company earns income from grants for research and commercialization activities. On November 6, 2012, the Company was awarded a milestone-based grant totaling up to $8.3 million from the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna MDx platform for use in limited resource settings. Upon execution of the grant agreement, the Company received $2.6 million to fund subsequent research and development activities and received milestone payments totaling $2.5 million in 2013. On September 10, 2014, the Company entered into an amended grant agreement with the Bill and Melinda Gates Foundation for additional funding of up to $12.6 million with the intent to accelerate the development of the Savanna MDx platform in the developing world. Upon execution of the amended grant agreement, the Company received $10.6 million in cash. The Company received a payment of $2.4 million in April 2015 and expects to receive the remaining milestone payment of up to $2.8 million in 2016. Under the original and amended grant agreements, the Company recognizes grant revenue on the basis of the lesser of the amount recognized on a proportional performance basis or the amount of cash payments that are non-refundable as of the end of each reporting period. The Company recognized $1.2 million and $0.7 million for the three months ended March 31, 2015 and 2014, respectively, as grant revenue associated with this grant. The Company classified $3.5 million and $3.1 million of funds received from the Bill and Melinda Gates Foundation as restricted cash as of March 31, 2015 and December 31, 2014, respectively. In addition, the Company has classified $5.1 million and $6.3 million as deferred grant revenue as of March 31, 2015 and December 31, 2014, respectively.
	Fair Value Measurements
	The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable. The Company establishes reserves for estimated uncollectible accounts and believes its reserves are adequate.
	Collaborative Arrangement
	In July 2012, the Company entered into a collaborative arrangement with Life Technologies Corporation to develop molecular assays. ASC Topic 808, Collaborative Arrangements (“ASC 808”), defines a collaborative arrangement as an arrangement in which the parties are active participants and have exposure to significant risks. The Company is accounting for the joint development and commercialization activities with the third-party as a joint risk-sharing collaboration in accordance with ASC 808. There were no payments received during the three months ended March 31, 2015 and 2014, respectively. The Company recognized no reduction to research and development expense for the three months ended March 31, 2015 and 2014 relating to this collaborative arrangement. The Company does not expect payments in the remainder of 2015, as the development efforts are complete.
	In connection with the collaboration agreement, the Company also entered into a manufacturing and supply agreement with the same third party. As part of that agreement, the Company manufactures and sells assays to the third party. In March 2013, the Company also entered into a six-year instrument supply agreement (the “March 2013 Agreement”) with Life Technologies Corporation. Pursuant to the March 2013 Agreement, the Company paid $0.8 million for distribution rights to sell Life Technologies Corporation’s QuantStudio™ DX diagnostic laboratory instrument for use in the infectious disease field, along with the assays developed under the collaborative agreement. The distribution rights are included in intangible assets on the Consolidated Balance Sheets and are being amortized on a straight-line basis over the contractual term of six years.
	Recent Accounting Pronouncements
	In May 2014, the FASB issued guidance codified in ASC Topic 606, Revenue Recognition—Revenue from Contracts with Customers, which amends the guidance in former ASC Topic 605, Revenue Recognition. This guidance is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will generally need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The guidance is effective for annual reporting periods beginning after December 15, 2016, with early adoption prohibited. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2017. In April 2015, the FASB proposed a one-year deferral of the effective date for the new revenue standard. Under the proposal, the standard would be effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. The FASB plans to issue an exposure draft on the proposal and expects to seek public comment with a 30-day comment period.
	In August 2014, the FASB issued guidance codified in ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). Management will be required to make this evaluation for both annual and interim reporting periods and will make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in ASC Topic 450, Contingencies. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company expects to adopt the standard for the annual reporting period ended December 31, 2016 and is not expected to have an impact on the Company’s financial statements.
	In February 2015, the FASB issued guidance codified in ASU 2015-02 (Topic 810), Consolidation - Amendments to the Consolidation Analysis. The guidance affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. Specifically, the guidance amends (i) the identification of variable interests (fees paid to a decision maker or service provider), (ii) the Variable Interest Entity (VIE) characteristics for a limited partnership or similar entity and (iii) the primary beneficiary determination. The guidance is effective for annual periods ending after December 15, 2015 and for interim reporting periods starting in the first quarter 2016, with early adoption permitted. ASU 2015-02 is not expected to have a significant impact on the Company’s financial statements.
	In March 2015, the Emerging Issues Task Force (EITF) reached final consensus on Issue 14-B: Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The EITF affirmed its earlier decision to no longer require that a reporting entity that measures an investment using the net asset value (NAV) practical expedient categorize the investment in the fair value hierarchy. Instead, entities would be required to disclose the amount of such investments as a reconciling item between the balance sheet amounts and the amounts reported in the fair value hierarchy table. The EITF also affirmed its previous decision to narrow existing disclosure requirements to focus only on these investments. The final consensus would be applied retrospectively for annual periods ending after December 15, 2015 and for interim reporting periods starting in the first quarter 2016, with early adoption permitted. In April 2015, the FASB ratified the consensus and directed the staff to draft a final Accounting Standards Update for a vote by written ballot. The Company adopted the final consensus guidance beginning in the first quarter 2015 and it did not have an impact on the Company's financial statements.

Computation_of_Loss_Earnings_P

Computation of (Loss) Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation of (Loss) Earnings Per Share	Computation of Earnings (Loss) Per Share
	For the three months ended March 31, 2015 and 2014, basic earnings (loss) per share was computed by dividing net earnings (loss) by the weighted-average number of common shares outstanding, including vested restricted stock awards, during the period. Diluted earnings per share reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options as well as unvested restricted stock awards. Potential dilutive common shares were calculated using the treasury stock method and represent incremental shares issuable upon exercise of the Company’s outstanding stock options and unvested restricted stock awards. For periods in which the Company incurs losses, potentially dilutive shares are not considered in the calculation of net loss per share as their effect would be anti-dilutive. For periods in which the Company has earnings, stock options are excluded from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. For the three months ended March 31, 2015 and 2014, stock options totaling 1.0 million and 0.2 million, respectively, were not included in the computation of diluted Earnings Per Share ("EPS") because the exercise of such options would be anti-dilutive. As discussed in Note 6, the Company issued Convertible Senior Notes in December 2014. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in cash or shares of common stock ("conversion premium"). No conversion premium existed as of March 31, 2015, therefore, there was no dilutive impact from the Convertible Senior Notes to diluted EPS. In addition, for the three months ended March 31, 2015 and 2014, there were no participating securities.
	The following table reconciles the weighted-average shares used in computing basic and diluted earnings (loss) per share in the respective periods (in thousands):
		Three months ended March 31,
		2015	2014
	Shares used in basic earnings (loss) per share (weighted-average common shares outstanding)	34,641	34,199
	Effect of dilutive stock options and restricted stock awards	1,104	—
	Shares used in diluted earnings (loss) per share calculation	35,745	34,199

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories are recorded at the lower of cost (first-in, first-out) or market. Inventories consisted of the following, net of reserves of $0.6 million and $2.2 million at March 31, 2015 and December 31, 2014, respectively (in thousands):
		31-Mar-15		31-Dec-14
	Raw materials	$	10,801	$	10,472
	Work-in-process (materials, labor and overhead)	6,284		6,834
	Finished goods (materials, labor and overhead)	5,809		7,457
	Total inventories	$	22,894	$	24,763

Other_Current_Liabilities

Other Current Liabilities	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Other Current Liabilities	Other Current Liabilities
	Other current liabilities consist of the following (in thousands):
		March 31, 2015		31-Dec-14
	Customer incentives and rebates	$	8,858	$	4,729
	Accrued research and development costs	284		990
	Accrued interest	1,713		311
	Other	3,125		2,013
	Total other current liabilities	$	13,980	$	8,043

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company recognized income tax expense of $1.8 million and a benefit of $0.9 million for the three months ended March 31, 2015 and 2014, respectively, which represents an effective tax rate of 31% and 36%, respectively. For the three months ended March 31, 2015, the effective tax rate was lower compared to the first quarter of 2014 due primarily to the change in valuation allowance related to certain state deferred tax assets.
	The Company is subject to periodic audits by domestic and foreign tax authorities. The Company’s federal tax years for 2011 and forward are subject to examination by the U.S. authorities. With few exceptions, the Company’s state and foreign tax years for 2000 and forward are subject to examination by tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt
	3.25% Convertible Senior Notes due 2020
	In December 2014, the Company issued Convertible Senior Notes in the aggregate principle amount of $172.5 million. The Convertible Senior Notes have a coupon rate of 3.25% and are due 2020. Debt issuance costs of approximately $5.1 million were incurred of which $4.2 million consisted of underwriters fees, legal, accounting, and other professional fees and are recorded as a reduction to long-term debt and are being amortized to interest expense using the effective interest method over the six-year term of the Convertible Senior Notes. The remaining $0.9 million of debt issuance costs are allocated as a component of equity in additional paid-in capital. Deferred issuance costs related to the Convertible Senior Notes were $4.0 million and $4.1 million as of March 31, 2015 and December 31, 2014, respectively.
	The Convertible Senior Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock based on an initial conversion rate, subject to adjustment, of 31.1891 shares per $1,000 principal amount of the Convertible Senior Notes (which represents an initial conversion price of approximately $32.06 per share) on the business day immediately preceding September 15, 2020. The conversion will occur in the following circumstances and to the following extent: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015, if the last reported sales price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the notes in effect on each applicable trading day; (2) during the five consecutive business day period following any five consecutive trading day period in which the trading price per Convertible Senior Note for each such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; or (3) upon the occurrence of specified events described in the indenture for the Convertible Senior Notes. On or after September 15, 2020 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their notes for conversion at any time, regardless of the foregoing circumstances.
	It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment in cash equal to the “principal portion” and delivery of the "share amount" in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, or the conversion value during the 25-day observation period as described in the indenture for the Convertible Senior Notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price (“VWAP”) of the Company’s common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.
	The Company pays 3.25% interest per annum on the principal amount of the Convertible Senior Notes semi-annually in arrears in cash on June 15 and December 15 of each year. The Convertible Senior Notes mature on December 15, 2020. During the three months ended March 31, 2015, the Company recorded total interest expense of $2.7 million related to the Convertible Senior Notes of which $1.3 million related to the amortization of the debt discount and issuance costs and $1.4 million related to the coupon due semi-annually.
	If a fundamental change, as defined in the indenture for the Convertible Senior Notes, such as an acquisition, merger, or liquidation of the Company, occurs prior to the maturity date, subject to certain limitations, holders of the Convertible Senior Notes may require the Company to repurchase all or a portion of their Convertible Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase date.
	The Company accounts separately for the liability and equity components of the Convertible Senior Notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by measuring the fair value of a similar liability that does not have an associated conversion feature. Because the Company has no outstanding non-convertible public debt, the Company determined that senior, unsecured corporate bonds traded on the market represent a similar liability to the Convertible Senior Notes without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and with similar maturity, the Company estimated the implied interest rate of its Convertible Senior Notes to be 6.9%, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, which were defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Convertible Senior Notes, which resulted in a fair value of the liability component of $141.9 million upon issuance, calculated as the present value of implied future payments based on the $172.5 million aggregate principal amount. The $30.7 million difference between the cash proceeds of $172.5 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the Convertible Senior Notes were not considered redeemable.
	As a policy election under applicable guidance related to the calculation of diluted net earnings per share, the Company elected the combination settlement method as its stated settlement policy and applied the treasury stock method in the calculation of dilutive impact of the Convertible Senior Notes. The Convertible Senior Notes were not convertible as of March 31, 2015. If the Convertible Senior Notes were converted as of March 31, 2015, the if-converted value would not exceed the principal amount.
	The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices.
		March 31, 2015			December 31, 2014
	Principal amount of convertible notes outstanding	$	172,500		$	172,500
	Unamortized discount of liability component	(29,243		)	(30,403		)
	Unamortized debt issuance costs (1)	(3,981		)	(4,139		)
	Net carrying amount of liability component	139,276			137,958
	Less: current portion	—			—
	Long-term debt	$	139,276		$	137,958
	Carrying value of equity component, net of issuance costs	$	29,758		$	29,758
	Fair value of outstanding convertible senior notes (2)	187,411			190,613
	Remaining amortization period of discount on the liability component	5.8 years			6.0 years
	(1) Includes reclassification of $0.6 million from Prepaid expenses and other current assets and $3.5 million from Other non-current assets as of December 31, 2014.
	(2) Subsequent to the issuance of the financial statements for the year ended December 31, 2014, the Company discovered an error in its disclosure of the fair value of outstanding convertible senior notes.  The fair value of the Convertible Senior Notes at December 31, 2014 was $190.6 million instead of the amount originally disclosed in the Company’s Annual Report on Form 10-K, which inappropriately reflected only the book value of the long-term debt component of the Convertible Senior Notes, which was $142.1 million. The revision in the disclosure of fair value for the Convertible Senior Notes did not impact net loss as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Operations, Statements of Comprehensive (Loss) Income, Statements of Cash Flows or Statements of Stockholders' Equity as of December 31, 2014.
	Line of Credit
	On August 10, 2012, the Company entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”) that matures on August 10, 2017. As part of this amendment, the Company incurred an additional $1.0 million in deferred financing costs related to the Senior Credit Facility. The Company had previously recorded $0.6 million related to the prior credit facility. Deferred financing costs are amortized on a straight-line basis over the term of the Senior Credit Facility. As of March 31, 2015 the Company had deferred financing costs related to the Senior Credit Facility of $0.4 million included as a portion of other non-current assets and $0.3 million included as a portion of Prepaid expenses and Other current assets. As of December 31, 2014, the Company had deferred financing costs related to the Senior Credit Facility of $0.5 million included as a portion of Other non-current assets and $0.3 million included as a portion of Prepaid expenses and other current assets. The Senior Credit Facility bears interest at either the London Interbank Offered Rate (“LIBOR”) or the base rate, plus, in each case, an applicable margin. The base rate is equal to the highest of (i) the lender’s prime rate, (ii) the federal funds rate plus one-half of one percent and (iii) LIBOR plus one percent. The applicable margin is generally determined in accordance with a performance pricing grid based on the Company’s leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans. The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and dispositions of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; and limitation on transactions with affiliates. On December 1, 2014, the Company amended the Senior Credit Facility to allow for the issuance of the Convertible Senior Notes, and among other matters, provide for the conversion of, payment of principle or premiums on, and payment of interest on permitted convertible indebtedness. The Company is also subject to financial covenants, which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3:1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3:1 as of the end of each fiscal quarter. Funded debt is defined as outstanding borrowings on the Senior Credit Facility plus Convertible Senior Notes, less the Company’s domestic cash and cash equivalents in excess of $15.0 million. The Senior Credit Facility is secured by substantially all present and future assets and properties of the Company and is senior to the Convertible Senior Notes.
	As of March 31, 2015 and December 31, 2014, the Company had no borrowings outstanding. The Company had $107.5 million available under the Senior Credit Facility as of March 31, 2015. The Company’s ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company’s borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of March 31, 2015, the Company was in compliance with all financial covenants.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity
	Issuances and Repurchases of Common Stock
	During the three months ended March 31, 2015, 33,477 shares of common stock were issued in conjunction with the vesting and release of restricted stock units, 10,500 shares of common stock were issued due to the exercise of stock options and 25,080 shares of common stock were issued in connection with the Company’s employee stock purchase plan (the “ESPP”), resulting in net proceeds to the Company of approximately $0.6 million. Additionally, during the three months ended March 31, 2015, 12,892 shares of outstanding common stock with a value of $0.3 million were repurchased in connection with payment of minimum tax withholding obligations for certain employees relating to the lapse of restrictions on certain restricted stock awards. As of March 31, 2015, there was $50.0 million available under the Company’s share repurchase program, and there were no repurchases under the program during the three months ended March 31, 2015.
	Stock-Based Compensation
	The compensation expense related to the Company’s stock-based compensation plans included in the accompanying Consolidated Statements of Operations was as follows (in millions):
			Three months ended March 31,
			2015			2014
		Cost of sales	$	0.3		$	0.2
		Research and development	—			0.4
		Sales and marketing	0.5			0.3
		General and administrative	1.3			1.3
		Total stock-based compensation expense	$	2.1		$	2.2
	Total compensation expense recognized for the three months ended March 31, 2015 and 2014 includes $1.4 million and $1.4 million related to stock options and $0.7 million and $0.8 million related to restricted stock, respectively. As of March 31, 2015, total unrecognized compensation expense related to non-vested stock options was $9.0 million, which is expected to be recognized over a weighted-average period of approximately 2.8 years. As of March 31, 2015, total unrecognized compensation expense related to non-vested restricted stock was $3.2 million, which is expected to be recognized over a weighted-average period of approximately 3.1 years. Compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the three months ended March 31, 2015 and 2014.
	The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants.
			Three months ended March 31,
			2015		2014
		Risk-free interest rate	1.45	%	1.57	%
		Expected option life (in years)	6.22		5.75
		Volatility rate	40	%	42	%
		Dividend rate	—	%	—	%
	The weighted-average fair value of stock options granted during the three months ended March 31, 2015 and 2014 was $9.60 and $11.32, respectively. The Company granted 544,247 and 451,574 stock options during the three months ended March 31, 2015 and 2014, respectively. The weighted-average fair value of restricted stock granted during the three months ended March 31, 2015 and 2014 was $23.58 and $28.29, respectively. The Company granted 103,118 and 57,517 shares of restricted stock during the three months ended March 31, 2015 and 2014, respectively. The fair value of restricted stock is determined based on the closing market price of the Company’s common stock on the grant date.

Industry_and_Geographic_Inform

Industry and Geographic Information	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Industry and Geographic Information	Industry and Geographic Information
	The Company operates in one reportable segment. Sales to customers outside the U.S. represented $7.4 million (12%) and $7.1 million (15%) of total revenue for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015 and December 31, 2014, balances due from foreign customers were $5.2 million and $5.5 million, respectively.
	The Company had sales to individual customers in excess of 10% of total revenues, as follows:
			Three months ended March 31,
			2015		2014
		Customer:
		A	21	%	15	%
		B	18	%	18	%
		C	13	%	13	%
			52	%	46	%
	As of March 31, 2015 and December 31, 2014, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $7.3 million and $23.7 million, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Legal
	The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts that management believes are appropriate given the nature of its business. At March 31, 2015 and December 31, 2014, the Company had $0.3 million accrued as a liability for various legal matters where the Company deemed the liability probable and estimable.
	Licensing Arrangements
	The Company has entered into various other licensing and royalty agreements, which largely require payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $0.2 million and $0.3 million for the three months ended March 31, 2015 and 2014, respectively.
	Research and Development Agreements
	The Company has entered into various research and development agreements that provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones or resource expenditures. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At March 31, 2015 and December 31, 2014, total future commitments under the terms of these agreements are estimated at $1.8 million and $4.3 million, respectively. The commitments will fluctuate as we agree to new phases of development under the existing arrangements.
	Contingent Consideration
	In conjunction with the acquisition of BioHelix Corporation (“BioHelix”) in May 2013, the Company agreed to contingent consideration ranging from $5.0 million to $13.0 million upon achievement of certain research and development milestones and revenue targets through 2018. At December 31, 2014, all research and development milestones had been achieved and all payments related to research and development milestones had been disbursed. Payments related to the achievement of research and development milestones totaling $1.1 million were disbursed during the three months ended March 31, 2014. Payments of $0.1 million and $49,000 related to the revenue royalty earn-out were disbursed during the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, the current portion of the contingent consideration is $0.6 million and the non-current portion of the contingent consideration is $4.9 million. The fair value of the remaining contingent consideration related to the revenue royalty earn-out to be settled in cash is estimated based on the Monte Carlo Simulation Model.
	In August 2013, the Company completed a business combination accomplished by acquiring the assets of AnDiaTec GmbH & Co. KG (“AnDiaTec”), a privately-held, diagnostics company, based in Germany. The Company agreed to contingent consideration of up to €0.5 million ($0.5 million based on the March 31, 2015 currency conversion rate) upon achievement of certain revenue targets through 2018. As of March 31, 2015, the current portion of the contingent consideration is $25,000 and the non-current portion of the contingent consideration is $0.1 million, based on the Monte Carlo Simulation Model. In addition, the Company agreed to pay the founder of AnDiaTec contingent payments of up to €3.0 million ($3.3 million based on the March 31, 2015 currency conversion rate) upon achievement of certain research and development milestones, subject to continued employment. The Company paid $0.4 million and $0.3 million for the achievement of agreed upon research and development milestones during the three months ended March 31, 2015 and 2014, respectively. In April 2015, the Company paid $0.5 million for the achievement of agreed upon research and development milestones. These costs are recorded as compensation expense included in research and development expense in the Consolidated Statements of Operations.

Lease_Obligation

Lease Obligation	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Lease Obligation	Lease Obligation
	In the fourth quarter of 2013, the Company entered into a lease for approximately 30,000 square feet of office space and moved the executive and administrative functions into this facility in the second quarter of 2014. The lease expires in 2022 with options to extend the lease for two additional five-year periods. This operating lease included a lease incentive for tenant improvements of $1.7 million, which has been included as a leasehold improvement in property, plant and equipment and as deferred rent in other non-current liabilities.
	During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million, of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company is amortizing the lease obligation over the new lease term. The amount of the monthly rental payments remains the same under the amendment. In April 2015, the lease agreement was amended to extend the timing to exercise the option to purchase the general partner’s interest in the partnership to June 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $0.3 million for each of the three months ended March 31, 2015 and 2014, respectively.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands):
		31-Mar-15									31-Dec-14
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash equivalents	$	3,059		$	—	$	—	$	3,059	$	3,057	$	—	$	—	$	3,057
	Total assets measured at fair value	$	3,059		$	—	$	—	$	3,059	$	3,057	$	—	$	—	$	3,057
	Liabilities:
	Contingent consideration	—			—		5,604		5,604		—		—		5,756		5,756
	Total liabilities measured at fair value	$	—		$	—	$	5,604	$	5,604	$	—	$	—	$	5,756	$	5,756
	There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 categories of the fair value hierarchy during the three month period ended March 31, 2015 and the year ended December 31, 2014.
	The Company used Level 1 inputs to determine the fair value of a portion of its cash equivalents, which primarily consist of funds held in a money market account, and as such, the carrying value of such cash equivalents approximates fair value. As of March 31, 2015 and December 31, 2014, the carrying value of these cash equivalents was $3.1 million.
	As of March 31, 2015, the Company invested the majority of its cash equivalents in a money market fund that is valued at net asset value ("NAV") per share and is not included in the table above. The NAV that was provided by the fund administrators was derived from the fair value of the underlying investment as of the reporting date. The Company uses the reported NAV per share to estimate the fair value of the fund of $175.0 million. Under normal conditions, the fund invests in high-quality, short-term money market instruments of domestic and foreign issuers. These instruments include bank obligations, government securities, asset-backed securities, commercial paper, corporate bonds, municipal securities, and repurchase agreements. These investments may have fixed, floating, or variable interest rates and may be obligations of U.S. or foreign issuers. More than 25% of the fund's total assets may be invested in U.S. dollar-denominated obligations of U.S. banks. Security selection is based on several factors including credit quality, yield, and maturity, while taking into account the fund's overall level of liquidity and weighted average maturity. There are no restrictions on the redemption of the investment and the Company is able to redeem the full value of the investment at the reporting date.
	The Company assesses the fair value of contingent consideration to be settled in cash related to acquisitions using the Monte Carlo Simulation Model for the royalty earn-out portion of the contingent liability. This is a Level 3 measurement. Significant assumptions used in the measurement include future royalty payments and the discount rate associated with the potential volatility of the acquired business. Due to changes in the estimated future royalty payments and a shorter discounting period, the fair value of the contingent consideration liabilities changed, resulting in a $42,000 loss recorded to cost of sales in the Consolidated Statements of Operations during the three months ended March 31, 2014. The Company recorded no changes to the fair value of the contingent consideration liabilities during the three months ended March 31, 2015.
	Changes in estimated fair value of contingent consideration liabilities from December 31, 2014 through March 31, 2015 are as follows (in thousands):
		Contingent consideration liabilities
		(Level 3 measurement)
	Balance at December 31, 2014	$	5,756
	Cash payments	(129		)
	Unrealized gain on foreign currency translation	(23		)
	Balance at March 31, 2015	$	5,604

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying unaudited consolidated financial statements of Quidel Corporation and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) have been included.
	The information at March 31, 2015, and for the three months ended March 31, 2015 and 2014, is unaudited. For further information, refer to the Company’s consolidated financial statements and footnotes thereto for the year ended December 31, 2014 included in the Company’s 2014 Annual Report on Form 10-K. Operating results for any quarter are historically seasonal in nature and are not necessarily indicative of the results expected for the full year.
	The Company recorded an immaterial reclassification of $0.2 million for the three months ended March 31, 2014 from general and administrative expense as previously reported in the Consolidated Statements of Operations to conform to current year interest expense presentation. The amortization of debt issuance costs and loan commitment fees had previously been recorded in general and administrative expense in the Consolidated Statements of Operations and the Company reclassified the amounts to more appropriately identify them as interest expense. The reclassification did not impact net income as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Cash Flows, or Statements of Comprehensive Income (Loss). Management evaluated the materiality of these prior year reclassifications both qualitatively and quantitatively and determined that these errors were not material to the previously reported financial statements.
	For 2015 and 2014, the Company’s fiscal year will end or has ended on January 3, 2016 and December 28, 2014, respectively. For 2015 and 2014, the Company’s first quarter ended on March 29, 2015 and March 30, 2014, respectively. For ease of reference, the calendar quarter end dates are used herein. The three month periods ended March 31, 2015 and 2014 each included 13 weeks, respectively.
Comprehensive (Loss) Income	Comprehensive Income (Loss)
	Comprehensive income (loss) includes foreign currency translation adjustments excluded from the Company’s Consolidated Statements of Operations.
Use of Estimates	Use of Estimates
	The preparation of financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, management evaluates its estimates, including those related to revenue recognition, customer programs and incentives, bad debts, inventories, intangible assets, software development costs, stock-based compensation, restructuring, contingencies and litigation, contingent consideration, the fair value of the debt component of convertible debt instruments, and income taxes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition	Revenue Recognition
	The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts that are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenue from product sales are recorded upon passage of title and risk of loss to the customer. Passage of title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return.
	A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheet as property and equipment. The instrument is depreciated on a straight-line basis over the shorter of the lease term or the life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Operations. The reagent rental agreements represent one unit of accounting as the instrument and consumables (reagents) are interdependent in producing a diagnostic result and neither has a stand-alone value with respect to these agreements. No revenue is recognized at the time of instrument placement. All revenue is recognized when the title and risk of loss for the diagnostic kits have passed to the customer.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. The Company also earns income from the licensing of technology.
	The Company earns income from grants for research and commercialization activities. On November 6, 2012, the Company was awarded a milestone-based grant totaling up to $8.3 million from the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna MDx platform for use in limited resource settings. Upon execution of the grant agreement, the Company received $2.6 million to fund subsequent research and development activities and received milestone payments totaling $2.5 million in 2013. On September 10, 2014, the Company entered into an amended grant agreement with the Bill and Melinda Gates Foundation for additional funding of up to $12.6 million with the intent to accelerate the development of the Savanna MDx platform in the developing world. Upon execution of the amended grant agreement, the Company received $10.6 million in cash. The Company received a payment of $2.4 million in April 2015 and expects to receive the remaining milestone payment of up to $2.8 million in 2016. Under the original and amended grant agreements, the Company recognizes grant revenue on the basis of the lesser of the amount recognized on a proportional performance basis or the amount of cash payments that are non-refundable as of the end of each reporting period. The Company recognized $1.2 million and $0.7 million for the three months ended March 31, 2015 and 2014, respectively, as grant revenue associated with this grant. The Company classified $3.5 million and $3.1 million of funds received from the Bill and Melinda Gates Foundation as restricted cash as of March 31, 2015 and December 31, 2014, respectively. In addition, the Company has classified $5.1 million and $6.3 million as deferred grant revenue as of March 31, 2015 and December 31, 2014, respectively.
Fair Value Measurements	Fair Value Measurements
	The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable. The Company establishes reserves for estimated uncollectible accounts and believes its reserves are adequate.
Collaborative Arrangement	Collaborative Arrangement
	In July 2012, the Company entered into a collaborative arrangement with Life Technologies Corporation to develop molecular assays. ASC Topic 808, Collaborative Arrangements (“ASC 808”), defines a collaborative arrangement as an arrangement in which the parties are active participants and have exposure to significant risks. The Company is accounting for the joint development and commercialization activities with the third-party as a joint risk-sharing collaboration in accordance with ASC 808. There were no payments received during the three months ended March 31, 2015 and 2014, respectively. The Company recognized no reduction to research and development expense for the three months ended March 31, 2015 and 2014 relating to this collaborative arrangement. The Company does not expect payments in the remainder of 2015, as the development efforts are complete.
	In connection with the collaboration agreement, the Company also entered into a manufacturing and supply agreement with the same third party. As part of that agreement, the Company manufactures and sells assays to the third party. In March 2013, the Company also entered into a six-year instrument supply agreement (the “March 2013 Agreement”) with Life Technologies Corporation. Pursuant to the March 2013 Agreement, the Company paid $0.8 million for distribution rights to sell Life Technologies Corporation’s QuantStudio™ DX diagnostic laboratory instrument for use in the infectious disease field, along with the assays developed under the collaborative agreement. The distribution rights are included in intangible assets on the Consolidated Balance Sheets and are being amortized on a straight-line basis over the contractual term of six years.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the FASB issued guidance codified in ASC Topic 606, Revenue Recognition—Revenue from Contracts with Customers, which amends the guidance in former ASC Topic 605, Revenue Recognition. This guidance is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will generally need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The guidance is effective for annual reporting periods beginning after December 15, 2016, with early adoption prohibited. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2017. In April 2015, the FASB proposed a one-year deferral of the effective date for the new revenue standard. Under the proposal, the standard would be effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. The FASB plans to issue an exposure draft on the proposal and expects to seek public comment with a 30-day comment period.
	In August 2014, the FASB issued guidance codified in ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). Management will be required to make this evaluation for both annual and interim reporting periods and will make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in ASC Topic 450, Contingencies. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company expects to adopt the standard for the annual reporting period ended December 31, 2016 and is not expected to have an impact on the Company’s financial statements.
	In February 2015, the FASB issued guidance codified in ASU 2015-02 (Topic 810), Consolidation - Amendments to the Consolidation Analysis. The guidance affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. Specifically, the guidance amends (i) the identification of variable interests (fees paid to a decision maker or service provider), (ii) the Variable Interest Entity (VIE) characteristics for a limited partnership or similar entity and (iii) the primary beneficiary determination. The guidance is effective for annual periods ending after December 15, 2015 and for interim reporting periods starting in the first quarter 2016, with early adoption permitted. ASU 2015-02 is not expected to have a significant impact on the Company’s financial statements.
	In March 2015, the Emerging Issues Task Force (EITF) reached final consensus on Issue 14-B: Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The EITF affirmed its earlier decision to no longer require that a reporting entity that measures an investment using the net asset value (NAV) practical expedient categorize the investment in the fair value hierarchy. Instead, entities would be required to disclose the amount of such investments as a reconciling item between the balance sheet amounts and the amounts reported in the fair value hierarchy table. The EITF also affirmed its previous decision to narrow existing disclosure requirements to focus only on these investments. The final consensus would be applied retrospectively for annual periods ending after December 15, 2015 and for interim reporting periods starting in the first quarter 2016, with early adoption permitted. In April 2015, the FASB ratified the consensus and directed the staff to draft a final Accounting Standards Update for a vote by written ballot. The Company adopted the final consensus guidance beginning in the first quarter 2015 and it did not have an impact on the Company's financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies Change in Accounting Principle (Table) (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The following table presents the effect of the retrospective application of this change in accounting principle on the Company’s Consolidated Balance Sheets as of December 31, 2014:
	Consolidated Balance Sheets (in thousands)	As Reported December 31, 2014		Effect of Change in Accounting Principle			After change in Accounting Principle
	ASSETS
	Current assets:
	Prepaid expenses and other current assets	$	3,554	$	(640	)	$	2,914
	Total current assets	275,121		(640		)	274,481
	Other non-current assets	4,565		(3,499		)	1,066
	Total assets	451,550		(4,139		)	447,411
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Long-term debt	142,097		(4,139		)	137,958
	Total liabilities and stockholders’ equity	451,550		(4,139		)	447,411

Computation_of_Loss_Earnings_P1

Computation of (Loss) Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Weighted-average shares, EPS	The following table reconciles the weighted-average shares used in computing basic and diluted earnings (loss) per share in the respective periods (in thousands):
		Three months ended March 31,
		2015	2014
	Shares used in basic earnings (loss) per share (weighted-average common shares outstanding)	34,641	34,199
	Effect of dilutive stock options and restricted stock awards	1,104	—
	Shares used in diluted earnings (loss) per share calculation	35,745	34,199

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consisted of the following, net of reserves of $0.6 million and $2.2 million at March 31, 2015 and December 31, 2014, respectively (in thousands):
		31-Mar-15		31-Dec-14
	Raw materials	$	10,801	$	10,472
	Work-in-process (materials, labor and overhead)	6,284		6,834
	Finished goods (materials, labor and overhead)	5,809		7,457
	Total inventories	$	22,894	$	24,763

Other_Current_Liabilities_Tabl

Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Other Current Liabilities	Other current liabilities consist of the following (in thousands):
		March 31, 2015		31-Dec-14
	Customer incentives and rebates	$	8,858	$	4,729
	Accrued research and development costs	284		990
	Accrued interest	1,713		311
	Other	3,125		2,013
	Total other current liabilities	$	13,980	$	8,043

Debt_Debt_Tables

Debt Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Convertible Senior Notes	The fair values of the respective notes outstanding were measured based on quoted market prices.
		March 31, 2015			December 31, 2014
	Principal amount of convertible notes outstanding	$	172,500		$	172,500
	Unamortized discount of liability component	(29,243		)	(30,403		)
	Unamortized debt issuance costs (1)	(3,981		)	(4,139		)
	Net carrying amount of liability component	139,276			137,958
	Less: current portion	—			—
	Long-term debt	$	139,276		$	137,958
	Carrying value of equity component, net of issuance costs	$	29,758		$	29,758
	Fair value of outstanding convertible senior notes (2)	187,411			190,613
	Remaining amortization period of discount on the liability component	5.8 years			6.0 years
	(1) Includes reclassification of $0.6 million from Prepaid expenses and other current assets and $3.5 million from Other non-current assets as of December 31, 2014.
	(2) Subsequent to the issuance of the financial statements for the year ended December 31, 2014, the Company discovered an error in its disclosure of the fair value of outstanding convertible senior notes.  The fair value of the Convertible Senior Notes at December 31, 2014 was $190.6 million instead of the amount originally disclosed in the Company’s Annual Report on Form 10-K, which inappropriately reflected only the book value of the long-term debt component of the Convertible Senior Notes, which was $142.1 million. The revision in the disclosure of fair value for the Convertible Senior Notes did not impact net loss as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Operations, Statements of Comprehensive (Loss) Income, Statements of Cash Flows or Statements of Stockholders' Equity as of December 31, 2014.
	Line of Cr

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Compensation Expense Related to Stock-Based Compensation Plans	The compensation expense related to the Company’s stock-based compensation plans included in the accompanying Consolidated Statements of Operations was as follows (in millions):
			Three months ended March 31,
			2015			2014
		Cost of sales	$	0.3		$	0.2
		Research and development	—			0.4
		Sales and marketing	0.5			0.3
		General and administrative	1.3			1.3
		Total stock-based compensation expense	$	2.1		$	2.2
Estimated Fair Value of Each Stock Option Award	The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants.
			Three months ended March 31,
			2015		2014
		Risk-free interest rate	1.45	%	1.57	%
		Expected option life (in years)	6.22		5.75
		Volatility rate	40	%	42	%
		Dividend rate	—	%	—	%

Industry_and_Geographic_Inform1

Industry and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Sales to Individual Customers in Excess of 10% of Total Revenues	The Company had sales to individual customers in excess of 10% of total revenues, as follows:
			Three months ended March 31,
			2015		2014
		Customer:
		A	21	%	15	%
		B	18	%	18	%
		C	13	%	13	%
			52	%	46	%

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands):
		31-Mar-15									31-Dec-14
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash equivalents	$	3,059		$	—	$	—	$	3,059	$	3,057	$	—	$	—	$	3,057
	Total assets measured at fair value	$	3,059		$	—	$	—	$	3,059	$	3,057	$	—	$	—	$	3,057
	Liabilities:
	Contingent consideration	—			—		5,604		5,604		—		—		5,756		5,756
	Total liabilities measured at fair value	$	—		$	—	$	5,604	$	5,604	$	—	$	—	$	5,756	$	5,756
Changes in Estimated Fair Value of Contingent Consideration Liabilities	Changes in estimated fair value of contingent consideration liabilities from December 31, 2014 through March 31, 2015 are as follows (in thousands):
		Contingent consideration liabilities
		(Level 3 measurement)
	Balance at December 31, 2014	$	5,756
	Cash payments	(129		)
	Unrealized gain on foreign currency translation	(23		)
	Balance at March 31, 2015	$	5,604

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended			12 Months Ended	1 Months Ended
	Nov. 06, 2012	Mar. 31, 2015	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Apr. 30, 2015	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Prepaid expenses and other current assets		$3,367,000						$2,914,000
Assets, Current		285,291,000						274,481,000
Other non-current assets		1,000,000						1,066,000
Assets		455,193,000						447,411,000
Long-term debt		139,276,000						137,958,000
Liabilities and Equity		455,193,000						447,411,000
Milestone payments received			10,600,000		2,500,000
Reimbursement related to research and development expense		0
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General and administrative expense reclassified as interest expense				200,000
Revenue Recognition [Abstract]
Company milestone-based grant	8,300,000	12,600,000
Fund received for research and development activities	2,600,000
Company's expectation to receive milestone payment in 2016		2,800,000
Company grant revenue		1,200,000		700,000
Restricted cash		3,465,000						3,127,000
Deferred grant revenue		5,118,000						6,330,000
Distribution rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquisition of distribution rights						800,000
Distributions rights, contract term						6 years
Subsequent Event [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Milestone payments received							2,400,000
Scenario, previously reported [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Prepaid expenses and other current assets								3,554,000
Assets, Current								275,121,000
Other non-current assets								4,565,000
Assets								451,550,000
Long-term debt								142,097,000
Liabilities and Equity								451,550,000
New Accounting Pronouncement, Early Adoption, Effect [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Prepaid expenses and other current assets								-640,000
Assets, Current								-640,000
Other non-current assets								-3,499,000
Assets								-4,139,000
Long-term debt								-4,139,000
Liabilities and Equity								($4,139,000)

Computation_of_Loss_Earnings_P2

Computation of (Loss) Earnings Per Share - Additional Information (Detail) (Stock options [Member])	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Stock options [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from calculation of diluted (loss) earnings per share ("EPS")	1	0.2

Computation_of_Loss_Earnings_P3

Computation of (Loss) Earnings Per Share - Basic and Diluted EPS (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Diluted net income per share:
Weighted average common shares outstanding — basic	34,641	34,199
Effect of dilutive stock options and restricted stock awards	1,104	0
Weighted average common shares outstanding — diluted	35,745	34,199

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]
Net of reserves, inventories	$0.60	$2.20

Inventories_Summary_of_Invento

Inventories - Summary of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$10,801	$10,472
Work-in-process (materials, labor and overhead)	6,284	6,834
Finished goods (materials, labor and overhead)	5,809	7,457
Total inventories	$22,894	$24,763

Other_Current_Liabilities_Othe

Other Current Liabilities - Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Customer incentives and rebates	$8,858	$4,729
Accrued research and development costs	284	990
Accrued interest	1,713	311
Other	3,125	2,013
Total other current liabilities	$13,980	$8,043

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
(Benefit) provision for income taxes	($1,803)	$864
Effective tax rate	31.00%	36.00%

Debt_Convertible_Senior_Notes_

Debt Convertible Senior Notes Textual -Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 08, 2014
	D
Convertible Debt [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Convertible Senior Notes, face amount			$172,500,000
Carrying value of equity component, net of issuance costs	29,758,000		29,758,000	30,700,000
Senior Credit Facility, applicable margin	3.25%
Interest Expense, Debt	2,700,000
Debt issuance cost	5,100,000
Deferred financing costs			4,200,000
Remaining amortization period of discount on the liability component	5 years 9 months 0 days	6 years	6 years 0 months 0 days
Adjustments to additional paid in capital	900,000
Convertible Senior Notes, conversion ratio	31.1891
Convertible Senior Notes, conversion price			$32.06
Convertible Senior Notes, threshold trading days	20
Convertible Senior Notes, threshold consecutive trading days	30 years 0 months 0 days
Convertible Senior Notes, threshold percentage of stock price trigger	130.00%
Convertible Senior Notes, threshold consecutive business days	5 days
Convertible Senior Notes, threshold consecutive trading days, following consecutive business days	5 days
Convertible Senior Notes, threshold percentage of stock price trigger, following consecutive business days	98.00%
Convertible Senior Notes, observation period	25 days
Amortization of debt discount (premium)	1,300,000
Interest expense, Convertible Senior Notes, excluding amortization	1,400,000
Convertible Senior Notes, fair value disclosures			141,900,000
Other Current Assets [Member]
Debt Instrument [Line Items]
Deferred financing costs	300,000		300,000
Other Current Assets [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Deferred financing costs			-600,000
Other Current Assets [Member] | Convertible Debt [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Deferred financing costs	3,981,000		4,139,000
Other non-current assets [Member]
Debt Instrument [Line Items]
Deferred financing costs	400,000		500,000
Other non-current assets [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Deferred financing costs			($3,500,000)

Debt_Convertible_Notes_Details

Debt Convertible Notes (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 08, 2014
Debt Instrument [Line Items]
Long-term debt	$139,276		$137,958
Convertible Debt [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Principal amount of convertible notes outstanding	172,500		172,500
Unamortized discount of liability component	-29,243		-30,403
Unamortized debt issuance costs			-4,200
Net carrying amount of liability component	139,276		137,958
Less: current portion	0		0
Long-term debt	139,276		137,958
Carrying value of equity component, net of issuance costs	29,758		29,758	30,700
Fair value of outstanding convertible senior notes (2)	187,411		190,613
Remaining amortization period of discount on the liability component	5 years 9 months 0 days	6 years	6 years 0 months 0 days
Other Current Assets [Member]
Debt Instrument [Line Items]
Unamortized debt issuance costs	-300		-300
Other Current Assets [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Unamortized debt issuance costs			600
Other Current Assets [Member] | Convertible Debt [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Unamortized debt issuance costs	-3,981		-4,139
Other non-current assets [Member]
Debt Instrument [Line Items]
Unamortized debt issuance costs	-400		-500
Other non-current assets [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Unamortized debt issuance costs			3,500
Scenario, previously reported [Member]
Debt Instrument [Line Items]
Long-term debt			142,097
Scenario, previously reported [Member] | Convertible Debt [Member] | Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Net carrying amount of liability component			$142,100

Line_of_Credit_Additional_Info

Line of Credit - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Aug. 10, 2012
Line of Credit Facility [Line Items]
Line of Credit Facility, Funded Debt	$15,000,000
Long-term Line of Credit	0
Amount available under the Senior Credit Facility	107,500,000
Line of credit facility covenant compliance	the Company was in compliance with all financial covenants.
Other non-current assets [Member]
Line of Credit Facility [Line Items]
Deferred financing costs	400,000	500,000
Other Current Assets [Member]
Line of Credit Facility [Line Items]
Deferred financing costs	300,000	300,000
Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility			140,000,000
Senior Credit Facility, maturity date	10-Aug-17
Deferred financing costs	1,000,000
Senior Credit Facility, adjusted EBITDA ratio	3
Senior Credit Facility, interest coverage ratio	3
Senior Credit Facility [Member] | Scenario, previously reported [Member]
Line of Credit Facility [Line Items]
Deferred financing costs	$600,000
Senior Credit Facility [Member] | LIBOR [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin	1.25%
Senior Credit Facility [Member] | LIBOR [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin	2.50%
Senior Credit Facility [Member] | Base rate loans [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin	0.25%
Senior Credit Facility [Member] | Base rate loans [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin	1.50%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued in conjunction with the vesting and release of restricted stock units	33,477
Common stock issued due to exercise of stock options	10,500
Common stock issued in connection with employee stock purchase plan	25,080
Employee stock purchase plan, net proceeds	$600,000
Repurchase of common stock, shares	12,892
Repurchase of common stock	-337,000	-1,951,000
Amount available under the share repurchase program	50,000,000
Shares repurchase under the share repurchase program	0
Share-based compensation expense recognized	2,100,000	2,200,000
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	1,400,000	1,400,000
Total unrecognized compensation expense related to non-vested stock options	9,000,000
Expected weighted-average period of recognition for unrecognized compensation expense	2 years 9 months 0 days
Weighted-average grant date fair value of stock options granted	$9.60	$11.32
Stock options granted	544,247	451,574
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	700,000	800,000
Expected weighted-average period of recognition for unrecognized compensation expense	3 years 1 month 0 days
Total unrecognized compensation expense related to non-vested restricted stock	$3,200,000
Weighted-average grant date fair value of stock options granted	$23.58	$28.29
Stock options granted	103,118	57,517

Stockholders_Equity_Compensati

Stockholders' Equity - Compensation Expense Related to Stock-Based Compensation Plans (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$2.10	$2.20
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0.3	0.2
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	0.4
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0.5	0.3
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$1.30	$1.30

Stockholders_Equity_Estimated_

Stockholders' Equity - Estimated Fair Value of Each Stock Option Award (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Risk-free interest rate	1.45%	1.57%
Expected option life (in years)	6 years 2 months 20 days	5 years 9 months 0 days
Volatility rate	40.00%	42.00%
Dividend rate	0.00%	0.00%

Industry_and_Geographic_Inform2

Industry and Geographic Information - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Segment
Revenue, Major Customer [Line Items]
Number of reportable segments	1
Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	10.00%
Customer Concentration Risk [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Sales to customers outside the U.S.	7.4	$7.10
Accounts receivable	5.2		5.5
Customer Concentration Risk [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	52.00%	46.00%
Customer Concentration Risk [Member] | Sales [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	12.00%	15.00%
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	7.3		23.7
Credit Concentration Risk [Member] | Accounts receivable [Member] | Minimum [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	10.00%		10.00%

Industry_and_Geographic_Inform3

Industry and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenues (Detail) (Sales [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue, Major Customer [Line Items]
Sales percentage	10.00%
Customer Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Sales percentage	52.00%	46.00%
Customer Concentration Risk [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Sales percentage	21.00%	15.00%
Customer Concentration Risk [Member] | Customer B [Member]
Revenue, Major Customer [Line Items]
Sales percentage	18.00%	18.00%
Customer Concentration Risk [Member] | Customer C [Member]
Revenue, Major Customer [Line Items]
Sales percentage	13.00%	13.00%

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail)

3 Months Ended

3 Months Ended

1 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

31-May-13

31-May-13

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Aug. 31, 2013

Aug. 31, 2013

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Dec. 31, 2014

Apr. 30, 2015

USD ($)

USD ($)

USD ($)

Research and development milestones [Member]

Research and development milestones [Member]

BioHelix [Member]

BioHelix [Member]

BioHelix [Member]

BioHelix [Member]

Andiatec Acquisition [Member]

Andiatec Acquisition [Member]

Andiatec Acquisition [Member]

Andiatec Acquisition [Member]

Andiatec Acquisition [Member]

Claims and litigation [Member]

Claims and litigation [Member]

Research and Development Agreements [Member]

Research and Development Agreements [Member]

Subsequent Event [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Minimum [Member]

Maximum [Member]

USD ($)

Research and development milestones [Member]

Research and development milestones [Member]

Maximum [Member]

Maximum [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Research and development milestones [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Sale Leaseback Transaction [Line Items]

Accrued in other current liabilities

$13,980,000

$8,043,000

$300,000

$300,000

Company had royalty and license expenses relating to those agreements

200,000

300,000

Current commitments

1,800,000

4,300,000

Contingent consideration

5,000,000

13,000,000

3,300,000

3,000,000

500,000

500,000

Payment of contingent consideration

129,000

1,109,000

1,100,000

Payments for Royalties

100,000

49,000

Current portion of contingent consideration

598,000

733,000

600,000

25,000

Contingent consideration non-current portion

5,006,000

5,023,000

4,900,000

100,000

Milestone payments paid

$400,000

$300,000

$500,000

Lease_Obligation_Additional_In

Lease Obligation - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 1999	Dec. 31, 2013
	Lease			sqft
Sale Leaseback Transaction [Line Items]
Lease expiration year	2022
Number of extension	2
Extend the lease options	5 years
Incentive from Lessor	$1.70
Lease payments		0.3
San Diego facility [Member]
Sale Leaseback Transaction [Line Items]
Number of extension	3
Extend the lease options	5 years
Facility sold			15
Capital contributed			3.8
Cash transaction, netting			7
Partnership that acquired the facility	25.00%
Amended terms	10 years
Amended term lease extended ending date	31-Dec-19
Lease payments	$0.30
Property Subject to Operating Lease [Member]
Sale Leaseback Transaction [Line Items]
Area of real estate property				30,000

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Assets:
Total assets measured at fair value	$3,059	$3,057
Liabilities:
Total liabilities measured at fair value	5,604	5,756
Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	5,604	5,756
Level 1 [Member]
Assets:
Total assets measured at fair value	3,059	3,057
Liabilities:
Total liabilities measured at fair value	0	0
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash Equivalents, at Carrying Value	3,059	3,057
Assets:
Total assets measured at fair value	3,059	3,057
Level 1 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	0	0
Level 2 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Total liabilities measured at fair value	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets:
Total assets measured at fair value	0	0
Level 2 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	0	0
Level 3 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Total liabilities measured at fair value	5,604	5,756
Level 3 [Member] | Money Market Funds [Member]
Assets:
Total assets measured at fair value	0	0
Level 3 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	$5,604	$5,756

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Transfer of assets and liabilities between levels	$0
Amount outstanding under the Senior Credit Facility	0
Loss recorded in research and development due to change in fair value of contingent consideration liabilities	0	42,000
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, Fair Value Disclosure	175,000,000
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash Equivalents, at Carrying Value	$3,059,000		$3,057,000

Fair_Value_Measurements_Change

Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	$5,604	$5,756
Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	5,604	5,756
Cash payments	-129
Unrealized gain on foreign currency translation	-23
Balance at March 31, 2015	5,604
Commitments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	5,604	5,756
Commitments [Member] | Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	$5,604	$5,756